TET Systems v. Rejuvenate Bio: Inducible Gene Expression Patents Dismissed With Prejudice
TET Systems Holding GmbH & Co. KG filed suit against Rejuvenate Bio, Inc. and two individual defendants in the Southern District of California asserting two patents covering tetracycline-inducible transcription control technology. The plaintiff voluntarily dismissed its complaint with prejudice under Rule 41 just 57 days after filing, before defendants filed any responsive pleading.
A 57-Day IP Dispute Over Foundational Gene Switch Technology
TET Systems Holding GmbH & Co. KG — a German entity holding foundational intellectual property in tetracycline-regulated gene expression — initiated an infringement action in the Southern District of California on 30 September 2024 against Rejuvenate Bio, Inc., a biotech company focused on gene therapy-based approaches to age reversal, alongside two named individuals, Daniel Oliver and Noah Davidsohn. The asserted patents, USRE049583E (a reissued patent) and US9181556B2, cover inducible expression systems and tetracycline-controlled transcription sequences — core enabling technology in modern gene regulation research and therapeutic development.
The case ended on 26 November 2024 when TET Systems filed a voluntary dismissal with prejudice under Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure. Critically, the defendants had not yet filed a responsive pleading or moved for summary judgment at the time of dismissal, meaning TET Systems was entitled to dismiss unilaterally. The with-prejudice designation, however, goes beyond a standard unilateral dismissal — it permanently bars TET Systems from re-asserting the same claims against these defendants in any future action.
The 57-day resolution is strikingly short and suggests that the dispute may have been resolved through private negotiation, licensing agreement, or a strategic recalibration by the plaintiff — none of which are reflected in the public record. The choice of with-prejudice dismissal, rather than without-prejudice, is commercially significant and typically signals that something of value was exchanged or that the plaintiff had a definitive reason to foreclose future litigation. What precisely drove that decision remains unknown from the docket alone.
Filing to Voluntary dismissal in 57 days
57-day lifespan — well below the median district court patent case duration of 2–3 years
Dismissed with prejudice: what Rule 41 finality means for both parties
Rule 41(a)(1)(A)(i) allows unilateral dismissal — but with prejudice is permanent
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss without a court order before the defendant serves an answer or motion for summary judgment. TET Systems exercised this right but elected a with-prejudice designation. That election converts what would otherwise be a procedurally neutral exit into a final judgment on the merits — permanently extinguishing TET Systems’ right to sue these defendants on the same claims.
Voluntary — but finalTET Systems permanently surrenders its infringement claims against these defendants
By dismissing with prejudice, TET Systems has foreclosed any future enforcement of USRE049583E and US9181556B2 against Rejuvenate Bio, Daniel Oliver, and Noah Davidsohn arising from the same accused conduct. This is a meaningful concession. It may reflect a licensing deal, settlement, or a strategic decision that litigation was no longer commercially viable — but the public record does not confirm which.
No re-filing permittedRejuvenate Bio and individual defendants receive permanent protection from these claims
The with-prejudice dismissal effectively delivers the defendants a litigation-proof outcome on these specific claims without having to litigate a single substantive issue. Rejuvenate Bio, Oliver, and Davidsohn face no ongoing liability under this action and cannot be re-sued by TET Systems on the same patent claims. Whether any licensing terms were agreed privately is not disclosed in the docket.
Claims permanently barredWith-prejudice exit typically signals resolution — not mere abandonment
In patent practice, a voluntary dismissal with prejudice before any responsive pleading strongly suggests the parties reached an out-of-court resolution — commonly a license, covenant not to sue, or settlement. For companies using tetracycline-inducible expression systems in gene therapy pipelines, this case signals that TET Systems is actively monitoring commercial use of its foundational IP, even if this particular dispute concluded quietly.
Likely private resolutionFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | TET Systems Holding Gmbh & Co., KG | Company | German gene regulation IP holding entity — holder of USRE049583E and US9181556B2Search in Eureka ↗ |
| Defendant | Rejuvenate Bio, Inc. | Company | Rejuvenate Bio, Inc. — biotech firm developing gene therapy approaches for longevity and age reversalSearch in Eureka ↗ |
| Co-Defendant | Daniel Oliver | Individual | Search in Eureka ↗ |
| Co-Defendant | Noah Davidsohn | Individual | Search in Eureka ↗ |
| Plaintiff counsel | John Olsen | Attorney | Counsel for TET Systems Holding Gmbh & Co., KGSearch in Eureka ↗ |
| Plaintiff law firm | The Law Office of John F. Olsen LLC | Law Firm | Representing TET Systems Holding Gmbh & Co., KGSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and expressly notes that defendants had not filed a responsive pleading or moved for summary judgment — the precise statutory condition enabling unilateral plaintiff dismissal. The with-prejudice designation is the operative legal fact: it transforms a procedural exit into a merits-equivalent bar. No court order was required, yet the outcome carries the same preclusive effect as a final judgment, permanently releasing these defendants from liability on the asserted claims.
USRE049583E & US9181556B2 — Tetracycline-Inducible Gene Expression Systems
USRE049583E is a reissued United States patent — meaning the original grant was surrendered and reissued, potentially with amended or broadened claims, through a USPTO reissue proceeding. It covers inducible expression systems controlled by tetracycline, a foundational technology enabling conditional gene activation in research and therapeutic contexts. US9181556B2 covers tetracycline-inducible transcription control sequences and methods of use. Both patents originate from TET Systems’ core platform around Tet-On and Tet-Off gene switch technology, which has been a cornerstone of molecular biology tools for decades.
These patents sit at the infrastructure layer of gene therapy and synthetic biology — companies developing gene therapies, CAR-T platforms, viral vectors, or inducible transgenic models frequently rely on tetracycline-regulated expression. TET Systems has historically licensed this technology broadly, but the reissued status of USRE049583E suggests active portfolio management to maintain or extend claim coverage. For Rejuvenate Bio — which focuses on epigenetic reprogramming and longevity gene therapies — these patents are directly relevant to core research methodology and therapeutic vector design.
Should your gene therapy pipeline run an FTO against USRE049583E?
Any R&D team, biotech startup, or CRO working with tetracycline-inducible expression systems — including Tet-On, Tet-Off, or rtTA-based constructs — should treat these patents as live enforcement risks. This case demonstrates that TET Systems actively monitors commercial use of its portfolio. If your organisation uses doxycycline- or tetracycline-regulated promoters in therapeutic constructs, research tools, or licensed platforms, an FTO analysis against USRE049583E and US9181556B2 is not optional risk management — it is foundational due diligence.
PatSnap Eureka’s FTO Search Agent can map your specific constructs and expression cassette architectures against the claims of USRE049583E and US9181556B2, identify relevant prior art, and flag design-around opportunities. Eureka also surfaces the full reissue prosecution history, enabling claim-by-claim scope analysis. For in-house IP teams preparing freedom-to-operate opinions or licensing due diligence ahead of Series B or IND filings, Eureka reduces the time to a defensible FTO position from weeks to days.
Run a freedom-to-operate analysis on USRE049583E to assess your product’s exposure
Run FTO in Eureka →Similar Patent Disputes: Inducible Gene Expression & Biotech Platform IP
Other infringement actions involving tetracycline-regulated gene expression patents and foundational biotech platform IP in U.S. district courts, including the Southern District of California.
What this case signals for the gene expression and gene therapy IP landscape
TET Systems’ swift enforcement action — and equally swift with-prejudice exit — reveals a calculated approach to protecting foundational inducible gene expression IP.
Foundational gene switch patents remain actively enforced against biotech startups
USRE049583E and US9181556B2 cover enabling technology that underpins a wide range of gene therapy and synthetic biology applications. TET Systems’ willingness to file suit against a relatively early-stage longevity biotech firm signals that holders of foundational platform IP are actively scanning for unlicensed commercial use — even in emerging therapeutic areas like age reversal.
Pre-answer dismissal with prejudice is a strong indicator of a private licensing deal
When a plaintiff files with prejudice before the defendant even responds, it typically suggests the litigation was used as a negotiating lever. IP teams at companies working with tetracycline-inducible systems should treat this pattern as a signal to audit their licensing position proactively — before a complaint is the first contact they receive.
TET v Rejuvenate — key questions answered
TET Systems asserted two patents: USRE049583E (a reissued patent covering inducible expression systems) and US9181556B2 (covering tetracycline-inducible transcription control sequences). Both relate to TET Systems’ core Tet-regulated gene switch platform. The case was filed in the Southern District of California on 30 September 2024.
The public record does not disclose the reason. TET Systems filed a voluntary dismissal with prejudice under Rule 41(a)(1)(A)(i) just 57 days after filing, before any responsive pleading was served. A with-prejudice designation typically suggests the parties reached a private resolution — such as a licensing agreement or settlement — though this is not confirmed by the docket.
Dismissal with prejudice permanently bars TET Systems from re-filing the same infringement claims against Rejuvenate Bio, Daniel Oliver, and Noah Davidsohn. The dismissal carries the preclusive effect of a final judgment on the merits. Rejuvenate Bio cannot be sued again by TET Systems on these specific claims arising from the same accused conduct.
The complaint named Daniel Oliver and Noah Davidsohn alongside the corporate defendant Rejuvenate Bio, Inc. Naming founders or executives individually is a recognised patent enforcement strategy that increases personal legal exposure and can accelerate settlement discussions. The individuals appear to be associated with Rejuvenate Bio’s operations, though their specific roles are not detailed in the available docket data.
A reissued patent (RE) is one where the original patent was surrendered to the USPTO and reissued with corrected or amended claims. Reissues filed within two years of the original grant can broaden claim scope. USRE049583E’s reissued status suggests TET Systems actively managed claim coverage, potentially capturing expression system configurations not covered under the original grant — a factor any FTO analysis must address carefully.
PatSnap Eureka searches patents and litigation data to answer instantly.